X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-06-22 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $132.60 | -26,400 | 179,248 | -13% | -$3,500,640 | ||||||
2026-06-22 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $132.54 | -80,000 | 1,015,987 | -7% | -$10,603,200 | ||||||
| M | 2026-06-22 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $0.95 | +109,200 | 823,475 | +15% | +$103,584 | |||||
| M | 2026-06-22 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.04 | -27,858 | 345,009 | -7% | -$725,495 | |||||
| D | 2026-06-22 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale+OE | $16.97 | -187,163 | 177,461 | -51% | -$3,176,865 | |||||
| D | 2026-06-22 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale+OE | $16.94 | -93,456 | 418,557 | -18% | -$1,583,145 | |||||
2026-06-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $87.32 | -291 | 120,414 | 0% | -$25,411 | ||||||
2026-06-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $87.32 | -346 | 119,346 | 0% | -$30,214 | ||||||
| D | 2026-06-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $87.32 | -1,688 | 842,919 | 0% | -$147,400 | |||||
| D | 2026-06-22 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $65.00 | -5,000 | 0 | -100% | -$325,000 | |||||
2026-06-22 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.47 | -114,746 | 942,485 | -11% | -$1,200,851 | ||||||
2026-06-22 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $103.75 | -31,798 | 613,762 | -5% | -$3,299,037 | ||||||
| DM | 2026-06-17 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale+OE | $94.72 | -478,198 | 617,663 | -44% | -$45,293,294 | |||||
| D | 2026-06-22 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale+OE | $99.00 | -2,500 | 50,195 | -5% | -$247,500 | |||||
2026-06-18 | RXRX | Recursion Pharmaceuticals, Inc. | Bumpus Namandje | Dir | S - Sale | $3.18 | -3,963 | 127,632 | -3% | -$12,602 | ||||||
2026-06-17 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $61.55 | -10,000 | 881,412 | -1% | -$615,488 | ||||||
| D | 2026-06-18 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.24 | -10,000 | 16,248 | -38% | -$402,400 | |||||
| D | 2026-06-18 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $40.21 | -15,000 | 1,647 | -90% | -$603,150 | |||||
2026-06-18 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $35.39 | -2,634 | 180,597 | -1% | -$93,217 | ||||||
2026-06-18 | CRDF | Cardiff Oncology, Inc. | Mohindru Mani | CEO | P - Purchase | $1.21 | +24,703 | 24,703 | New | +$29,891 | ||||||
2026-06-18 | CRDF | Cardiff Oncology, Inc. | Pace Gary W | Dir | P - Purchase | $1.22 | +30,000 | 1,356,376 | +2% | +$36,600 | ||||||
| M | 2026-06-17 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.89 | +2,300 | 300,566 | +1% | +$2,043 | |||||
| D | 2026-06-18 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $52.50 | -24,461 | 609,918 | -4% | -$1,284,205 | |||||
| D | 2026-06-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $53.00 | -10,000 | 166,245 | -6% | -$530,000 | |||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $156.12 | -4,615 | 49,975 | -8% | -$720,490 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $156.12 | -10,020 | 990,238 | -1% | -$1,564,310 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $156.12 | -2,157 | 56,521 | -4% | -$336,749 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $156.12 | -2,722 | 123,269 | -2% | -$424,956 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $156.12 | -4,175 | 291,876 | -1% | -$651,798 | ||||||
| D | 2026-06-17 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $19.00 | -2,176 | 62,371 | -3% | -$41,344 | |||||
| D | 2026-06-17 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $19.00 | -3,000 | 67,845 | -4% | -$57,000 | |||||
| M | 2026-06-15 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $17.41 | -106,160 | 1,405,898 | -7% | -$1,847,942 | |||||
| DM | 2026-06-15 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $160.00 | -93,575 | 154,647 | -38% | -$14,972,110 | |||||
| M | 2026-06-15 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.97 | +67,669 | 7,808,627 | +1% | +$1,689,818 | |||||
2026-06-15 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Dir | S - Sale | $27.29 | -283 | 203,672 | 0% | -$7,724 | ||||||
| DM | 2026-06-15 | ABOS | Acumen Pharmaceuticals, Inc. | Porter Derrell | Dir | S - Sale+OE | $2.33 | -32,300 | 35,500 | -48% | -$75,240 | |||||
| D | 2026-06-16 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | See Remarks | S - Sale+OE | $60.95 | -14,396 | 56,801 | -20% | -$877,436 | |||||
2026-06-15 | TARS | Tarsus Pharmaceuticals, Inc. | Goodrich Katherine | Dir | S - Sale | $62.08 | -2,954 | 2,233 | -57% | -$183,384 | ||||||
2026-06-15 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $62.12 | -12,500 | 106,786 | -10% | -$776,495 | ||||||
2026-06-15 | OCGN | Ocugen, Inc. | Johnson-Greene Treerita Essalima | CFO | P - Purchase | $1.23 | +21,000 | 521,350 | +4% | +$25,830 | ||||||
| D | 2026-06-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $51.37 | -53,336 | 1,639,897 | -3% | -$2,739,870 | |||||
| D | 2026-06-15 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale+OE | $81.67 | -26,137 | 120,705 | -18% | -$2,134,488 | |||||
| M | 2026-06-12 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $8.66 | +531,326 | 17,922,766 | +3% | +$4,599,903 | |||||
2026-06-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $123.92 | -3,000 | 124,234 | -2% | -$371,762 | ||||||
2026-06-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $125.40 | -3,000 | 171,646 | -2% | -$376,200 | ||||||
| D | 2026-06-15 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $60.12 | -1,964 | 0 | -100% | -$118,076 | |||||
2026-06-16 | AURA | Aura Biosciences, Inc. | Gibney Anthony S | See Remarks | S - Sale | $6.42 | -12,824 | 265,354 | -5% | -$82,330 | ||||||
| D | 2026-06-15 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $34.02 | -1,500 | 136,731 | -1% | -$51,030 | |||||
| M | 2026-06-11 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.96 | +7,685 | 2,742,574 | 0% | +$45,773 | |||||
2026-06-12 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.23 | -2,584 | 605,092 | 0% | -$5,767 | ||||||
2026-06-12 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.23 | -1,654 | 505,094 | 0% | -$3,692 | ||||||
2026-06-11 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $19.00 | -5,000 | 411,775 | -1% | -$95,000 | ||||||
2026-06-11 | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Dir | P - Purchase | $27.82 | +35,948 | 1,575,834 | +2% | +$999,983 | ||||||
| D | 2026-06-11 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $148.01 | -10,000 | 158,222 | -6% | -$1,480,139 | |||||
2026-06-10 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $83.38 | -20,000 | 1,095,987 | -2% | -$1,667,622 | ||||||
| M | 2026-06-09 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $7.44 | +1,027,722 | 17,391,440 | +6% | +$7,650,148 | |||||
| M | 2026-06-09 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.98 | +30,728 | 2,734,889 | +1% | +$183,692 | |||||
2026-06-09 | ABOS | Acumen Pharmaceuticals, Inc. | Fountain Nathan B | Dir | S - Sale | $2.23 | -6,400 | 48,150 | -12% | -$14,273 | ||||||
2026-06-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $69.84 | -402 | 119,692 | 0% | -$28,077 | ||||||
2026-06-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $69.84 | -884 | 120,705 | -1% | -$61,742 | ||||||
| D | 2026-06-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $69.84 | -2,265 | 844,607 | 0% | -$158,197 | |||||
2026-06-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $69.20 | -1,359 | 46,327 | -3% | -$94,046 | ||||||
2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | CFO | S - Sale | $1.30 | -2,884 | 208,491 | -1% | -$3,746 | ||||||
2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | See Remarks | S - Sale | $1.30 | -3,737 | 962,960 | 0% | -$4,854 | ||||||
2026-06-05 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | See Remarks | S - Sale | $1.30 | -558 | 126,491 | 0% | -$725 | ||||||
| D | 2026-06-05 | NBIX | Neurocrine Biosciences Inc | Sherwin Stephen A | Dir | S - Sale+OE | $165.32 | -25,000 | 15,860 | -61% | -$4,132,969 | |||||
2026-06-09 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.85 | +5,000 | 298,266 | +2% | +$4,250 | ||||||
2026-06-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.11 | -524 | 607,676 | 0% | -$1,106 | ||||||
2026-06-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.11 | -249 | 506,748 | 0% | -$526 | ||||||
2026-06-05 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.83 | +10,054 | 2,704,161 | 0% | +$58,596 | ||||||
| D | 2026-06-04 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.49 | -39,741 | 253,434 | -14% | -$695,070 | |||||
2026-06-04 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $18.00 | -11,000 | 416,775 | -3% | -$198,000 | ||||||
2026-06-04 | NBIX | Neurocrine Biosciences Inc | Norwalk Leslie V | Dir | S - Sale | $168.06 | -1,250 | 2,838 | -31% | -$210,072 | ||||||
| D | 2026-06-04 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $50.00 | -3,471 | 73,561 | -5% | -$173,550 | |||||
| D | 2026-06-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $78.71 | -5,500 | 205,648 | -3% | -$432,905 | |||||
2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $308.11 | -25,000 | 1,518,155 | -2% | -$7,702,825 | ||||||
2026-06-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $308.12 | -25,000 | 1,590,253 | -2% | -$7,702,984 | ||||||
2026-06-04 | INKT | Mink Therapeutics, Inc. | Ryan Barbara | Dir | S - Sale | $12.76 | -1,500 | 21,969 | -6% | -$19,141 | ||||||
| D | 2026-06-04 | KOD | Kodiak Sciences Inc. | Borgeson John A. | CFO | S - Sale+OE | $34.10 | -30,000 | 211,930 | -12% | -$1,023,009 | |||||
2026-06-04 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $7.18 | -23,033 | 2,827,788 | -1% | -$165,306 | ||||||
| D | 2026-06-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.62 | -40,000 | 883,735 | -4% | -$144,800 | |||||
2026-06-05 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | CEO, Pres | S - Sale | $3.58 | -23,588 | 2,175,796 | -1% | -$84,459 | ||||||
2026-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.70 | -464 | 14,970 | -3% | -$1,253 | ||||||
2026-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.70 | -15,380 | 248,313 | -6% | -$41,543 | ||||||
2026-06-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.70 | -731 | 67,297 | -1% | -$1,975 | ||||||
| D | 2026-06-04 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $54.50 | -1,000 | 0 | -100% | -$54,500 | |||||
| D | 2026-06-02 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale+OE | $156.22 | -36,937 | 22,374 | -62% | -$5,770,235 | |||||
2026-06-03 | RXRX | Recursion Pharmaceuticals, Inc. | Bumpus Namandje | Dir | S - Sale | $3.54 | -4,386 | 43,171 | -9% | -$15,526 | ||||||
2026-06-02 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.68 | -30,000 | 6,169,863 | 0% | -$110,400 | ||||||
| D | 2026-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $35.00 | -4,375 | 75,753 | -5% | -$153,125 | |||||
2026-06-01 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $9.24 | -12,000 | 180,962 | -6% | -$110,880 | ||||||
| DM | 2026-06-01 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $67.40 | -50,000 | 767,780 | -6% | -$3,370,008 | |||||
2026-06-01 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale | $50.55 | -3,925 | 284,384 | -1% | -$198,409 | ||||||
2026-06-01 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale | $50.14 | -9,812 | 16,079 | -38% | -$491,974 | ||||||
2026-06-02 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Dir | P - Purchase | $0.83 | +29,000 | 66,167 | +78% | +$24,145 | ||||||
2026-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.97 | -87,216 | 6,297,581 | -1% | -$172,191 | ||||||
| M | 2026-06-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $1.94 | -9,184 | 95,461 | -9% | -$17,813 | |||||
2026-06-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | CFO, Chief Business Officer | S - Sale | $1.97 | -19,360 | 379,900 | -5% | -$38,221 | ||||||
2026-06-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.20 | -6,643 | 372,867 | -2% | -$174,048 | ||||||
| D | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $25.66 | -14,853 | 0 | -100% | -$381,112 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |